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Abstract
Background: Sickle cell trait (SCT) for long has been regarded as a benign condition
and as such healthcare providers do little to nothing to mitigate adverse health
problems associated with sickle cell trait. An effective approach to improving health
outcome for those with SCT is to educate providers on SCT, its complications and
management. This study is aimed at evaluating the effectiveness of an educational
intervention on providers’ knowledge, attitude and practice regarding sickle cell trait.
Method: A quasi experiment study was conducted in Jackson Health System on 30
providers belonging to internal medicine team to evaluate their pre and post
knowledge, attitude and practice towards SCT.
Result: Out of 30 providers recruited for the study, 21 completed both the pretest and
posttest questionnaire giving a response rate of 70%. The overall score improved after
the educational intervention, however the overall mean score for pretest and posttest
was not significantly different (p = 0.223). There was a significant difference (p =
0.045) between the knowledge mean score for pretest and posttest. Attitude scores for
pretest and posttest were not significantly different (p= 0.545). A similar finding was
obtained for practice score (P-value 0.604).
Conclusion: Educational intervention was effective in improving knowledge, attitude
and practice of providers regarding sickle cell trait. Therefore this effort must be
sustained through continuous education within the institution to increase awareness
towards sickle cell trait among healthcare providers especially for new hires.

Key Words: Health care providers, African Americans, mitigation, Knowledge,
attitude, practice, sickle cell trait, genetic counseling, Rhabdomyolysis, status,
screening
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Introduction/Problem Statement
Sickle cell Trait and other sickle cell disorders disproportionately affect
African and Americans (CDC 2020). There is a lack of awareness of SCT and limited
number of providers are screening their African American patients for SCT. Very
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often many African American patients and their health care providers do not know
their sickle cell trait status and are also unaware that SCT has some adverse health
implications like sudden death, rhabdomyolysis and chronic kidney disease. This
knowledge gap exist because SCT status is not transferred during transition from
pediatric to adult care and does not exist in patients’ medical record. It is also not part
of history taking during initial encounter between patient and provider. Many African
American youths are actively involved in sports which predispose them to exertional
rhabdomyolysis and sudden death. And quite often we see or hear about black athletes
collapsing during sporting activities or during military training. If an individual is
identified to have SCT measure can be taken to avoid dehydration, heat stroke and
muscle breakdown during exercise. It can also reduce the incidence of sickle cell
disease through genetic counseling. Sickle cell trait is no longer a benign condition as
previously thought, therefore individuals who carry such traits should be evaluated on
regular basis and given the large number of people with SCT, it is important that
providers be aware of these associations. Awareness of SCT status by patient, families
and treating provider is very important.

Background
People with sickle cell trait even though they do not suffer serious medical problems
are often neglected and no action is taken to treat their potential medical conditions
before they progress into more serious health problems. There is a misconception that
SCT poses no serious health problem because individuals with SCT do not usually
manifest any visible symptoms as seen with sickle cell disease and as such individuals
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are often not screened (Mainous et al 2015). This problem is further compounded by
lack of awareness of SCT status by both patients and providers. Sickle cell trait occurs
in all 50 states of the United States but prevalence is disproportionately very high in
States with high black populations. Even though national mandatory newborn
screening has been instituted, yet government and some philanthropic organizations
who sponsor research into treatment and prevention of other diseases like HIV/AID,
tuberculosis, diabetes and osteoporosis have failed to attach same importance to sickle
cell disease and sickle cell trait. There are advertisement on television or billboards
educating black community about health implications of sickle cell trait. The
mandatory sickle cell disease and sickle cell trait screening for every newborn black
babies does not go far enough. Very often the data collected is not communicated to
PCP when patients transition to adolescents/adults. As many as 1.5% of babies born
in the United States (15.5 cases per 1000) have SCT (Ojodu et al 2014). Ojodu et al
(2014) also reported that there are no standardized methods or protocols for alerting
families or healthcare providers to this information, educating them about the
potential health outcomes that might be associated with the condition, or counseling
them about the impact that this might have on the family’s future reproductive
choices. By including educational materials and providing genetic counseling at the
same time that families are given positive SCT results, the occurrence and public
health burden of SCD might be reduced. Because people with SCT are at risk of
having a child with sickle cell disease if their partner also has SCT or one of several
other abnormal hemoglobin genes, it is important to properly inform them of their
status and educate them about possible health problems and reproductive
considerations (CDC 2020). Such knowledge will inform genetic counseling, effect
disease modifying measures, mitigate complications associated with SCT when
caught early, reduce morbidity and mortality in African Americans reduce health care
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cost and increase advocacy for sickle cell disease related disorders Housten et al
2016).

Problem Identification
Sickle cell disease is an inherited disease that affects the hemoglobin. The
disease distorts red blood cell into sickled or crescent shape which impedes blood
flow to the rest of the body. This blockage of blood flow leads to some serious health
problems including strokes, infections and episodes of pain called crises. Sickle cell
disease apart from causing significant morbidity and mortality in affected individual
also affects them socially due to a lot of stigma associated with this condition. Sickle
cell disease also has significant impact on the healthcare and economy of many
countries (Gardner 2018).When an individual inherits one sickle cell gene and one
normal gene, the individual has sickle cell trait which is a carrier state of sickle cell
disease. Carrier state is characterized by the presence of about 40% HbS, absence of
anemia, hematuria and inability to concentrate urine (Maakaron 2020). Carriers even
though they do not have the symptoms of sickle cell disease pose threat to SCD
because they have the capacity to pass on this trait to their children. If both parents are
carriers of sickle cell trait, there is a 25% chance that they will have a child with
sickle cell disease. People with sickle cell trait are often neglected because they show
no visible symptoms. Many African American patients do not know their sickle cell
trait status and neither do their providers. According to Creary et al (2017) only 16%
of individuals in their childbearing age who have SCT have knowledge of their status.
This is a serious problem because sickle cell trait has serious health implications for
African Americans. Sickle cell trait status is often missing in their medical records
because it is not included in routine history taking during emergency room or office
visits. People with SCT are often not screened because they are "not sick". This is a
huge gap in practice which must be bridged for better health outcome for African
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Americans who seek health care. Not knowing the SCT status for African American
clients has great public health implications for African Americans. Evidence has
shown that SCT has clinical sequelae such as exercise related injury, heat stroke,
sudden death, muscle breakdown during exercise (CDC 2016), renal complications,
venous thromboembolism, pregnancy related complications such as preeclampsia and
risk of having a child with sickle cell disease due to lack of genetic counseling (CDC
2020).
Scope of the Problem
Sickle cell traits affects about 300 million individuals worldwide and one third of
this number are in sub Saharan Africa (EL Ariss et al 2016). Gibson et al (2016) also
reported a prevalence of 25% in some parts of Africa and 60% in Saudi Arabia.
According to Maakaron (2020) Sickle cell trait and sickle cell disease are common in
individuals whose ancestors come from Africa, Mediterranean region (Turkey,
Greece, and Italy), Middle East (Saudi Arabia) and South Asia (India). Because of
forced and voluntary migration from areas with high prevalence such as Africa, India
and Middle East, SCD and SCT is now found all over the world and both the
incidence and prevalence will continue to increase in Western world (Maakaron 2020,
Ashorobi et al 2021). In the United States SCD and SCT disproportionately affect
blacks. The prevalence of SCT in the United States is 9% among African Americans
and 0.2% among Caucasians (Gibson et al 2016). According to CDC (2020),
approximately 3 million people has SCT in the United States nearly all of them
African Americans and many are unaware of their status. As many as 1.5% of babies
born in the United States (15.5 cases per 1000) have SCT (Ojodu et al 2014).1 in 13
black or African American babies is born with sickle cell trait (CDC 2020). Ojodu et
al (2014) in their study of the incidence of SCT in the United States reported that
every State and ethnic population has people living with SCT and the overall
incidence in the 44 participating States was 15.5 per 1000 newborns. They also
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reported that incidence varied greatly from State to State with Montana having the
lowest occurrence of 0.8 per 1000 newborns screened and Mississippi with the
highest 34.1 per 1000. Florida stands at 25. 9 per 1000 newborns. Among ethnic
groups blacks had 73.1 and Hispanics 6.9.
There is no sex predilection for SCD and SCT since they are not X-linked diseases.
The male to female ratio is 1:1 (Maakaron 2020)
Consequences of the Problem
Sickle cell trait was previously thought to a benign condition. Studies have
shown that SCT poses serious health risk. Under conditions of low oxygen like high
altitude, extreme exercise and high intensity physical training SCT may become a
pathologic risk factor (Maakaron 2020). Other complications associated with SCT
include rhabdomyolysis, splenic infarct, renal malignancy, thromboembolic disorders,
and hematuria (Tantawy 2014). All of these lead to increased morbidity, mortality and
lifestyle changes in black population. People with SCT are at risk of having a child
with sickle cell disease which is associated with huge financial burden to the patients
and their families as well as substantial cost to the society. Singh et al (2014) reported
that in 2004 United States spent $488 million from 113, 000 hospitalizations for sickle
cell related illnesses. Huo et al (2018) put the estimated incremental economic burden
of SCD at $2.98 billion per year in the United States. Breakdown of this cost shows
that 57% went to inpatient cost, 38% outpatient and 5% was out-of-pocket expenses
paid by the patient Since sickle cell disease is a lifelong condition and there is
presently no cure, this cost will only continue to rise. The only way to curtail these
excessive healthcare cost is through early diagnosis and treatment for individuals with
sickle cell trait and those with sickle cell disease.
Significance of this Problem
Sickle cell trait is not a completely benign condition, rather it is indeed a risk
factor for certain serious health disorders. If SCT individuals are denied routine
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check-ups, there will be increase in morbidity, mortality and changes in lifestyles in
black population. Quality of life will therefore be affected. Healthcare cost will
continue to skyrocket due to hospitalizations and disability. It is imperative to thrust
sickle cell status to limelight in order to give affected individuals best health outcome
by providing best medical advice and treatment to affected individuals. Also it is
important to break the cycle of transmission since two individuals with SCT have
25% of having a child with sickle cell disease. This can be achieved through genetic
counseling. Health care providers must educate their African American patients and
offer screening if status is unknown. This can reduce both the incidence and
prevalence of SCT and SCD. It is important to implement SCT screening not only for
newborns but for every individual whose status is unknown (Ashorobi et al 2021).
Memish et al (2011) in a study done in Saudi Arabia reported that a decrease in the
number of individuals with SCT marrying another carrier due to premarital screening
and genetic education.

Review of the Literature
Sickle cell disease is a lifelong inherited genetic disorder caused by sickling of
red blood cells. Individuals with sickle cell disease exhibit significant morbidity and
mortality. Symptoms include chronic anemia, acute chest syndrome, stroke, splenic
and renal dysfunctions, pain crises and susceptibility to bacterial infections. SCD
includes the lifelong challenges of managing the chronic illness while accessing and
navigating the health care system. The burdens of the disease can affect all aspects of
the lives of individuals with SCD to include physiological, psychological and social
wellbeing (Jenerette et al 2011).
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Sickle cell trait (SCT) is an inherited blood disorder that affects millions of
people worldwide. It is a carrier state for sickle cell disease considered to be a benign
condition. People with SCT are asymptomatic and do not show any of the symptoms
usually associated with sickle cell disease. Even though these carriers are not “sick”,
they are at risk for serious health complications such as exertional injury, sudden
death, chronic kidney disease and venous thromboembolism (Benenson et al 2018).
Knowledge and awareness of these potential health complications associated with
SCT is paramount both for the provider and the patient. This will help inform
appropriate medical interventions and genetic counseling early in order to reduce
morbidity and mortality and ensure best clinical outcome for people with SCT. This is
why the main objective of this study is to call attention to this group of people who
are often neglected by providers until serious health problem ensues. The study also
seeks to make healthcare providers who attended to at risk population aware of the
health risk posed by SCT and to emphasize the importance of screening and genetic
counseling. Benenson et al (2018) also emphasized that SCT screening should be
carefully documented and communicated to affected individuals and their providers.
Even though newborn screening is mandatory, this information is often not transferred
when these individuals transition to adolescents or adulthood because there is no
systematic way of doing so. Because of this gap in practice neither the patient nor
healthcare providers know the SCT status of their clients. In order to provide
evidence-based care to African Americans and other at risk populations, providers
must be aware of the SCT status of their clients, potential health complications and
routine management of individuals with SCT (Benenson et al 2018). This can only be
possible through screening of all individuals whose SCT status are unknown starting
during the initial encounter. The result should be part of the patients’ medical record

Sickle Cell Disease Stigmatization
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In addition to medical problems and complications, people with SCD also experience
psychosocial problems; stigmatization and labeling based on presumptions on the
nature of the disease. Even though sickle cell disease is a genetic disorder, racism
often play a big role in terms of healthcare equity, hindered accesses to care and less
funding support (Power-Hay et al 2020). Bulgin et al (2018) also reported that sickle
cell patients can experience bias for different reasons including race, minority status,
disease and socioeconomic status, delayed growth and recurrent acute pain. This
stigmatization may begin in childhood, the magnitude which is never assessed until
adolescence and adulthood (Okechukwu et al 2020). Jeanerette et al (2015) noted that
young adults with SCD are at risk for health related stigmatization due to many
challenges of the disease. People with SCD have suffered devaluation, judgement and
social disqualification of these individuals based on a health-related condition (Weiss
et al 2006). Pain is the hallmark feature of sickle cell disease. Almost all people with
sickle cell disease have painful episodes called crisis. This can last from hours to
days. Crisis can cause pain in the lower back, legs, joints and chest. Some people have
one episode every few years, others have many episodes each year and these crises
can be severe enough to warrant hospitalization. This is when the ordeal starts.
Ezenwa et al (2016) noted that people with sickle cell disease experience stigma
because frequency of their acute healthcare utilization and chronic use of opioids for
pain management. Many health care workers including doctors and nurses do not
understand what it means for a sickler to be in crisis. This lack of knowledge makes it
almost impossible for these patients to receive adequate and timely treatment. The
goal of treatment should be to manage and control symptoms and to limit the number
of crises. According to Jenerette et al (2011), health related stigma is increasingly
becoming a major health issue that should receive more attention. They went further
to say that young adults with sick cell disease are at risk for health-related
stigmatization due to many challenges of the disease. Stigmatization adds to the
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burden of individual and family affected by sickle cell disease and is associated with
adverse health outcomes (Ezenwa et al 2016). Satorious (2006), reported that stigma
evokes negative attitudes and feelings which may affect the type of care these people
receive., like receipt of timely and quality health care. Stigma has a significant impact
on the health and well-being of sickle cell patients. Health related stigma can have a
deleterious affect across the lifespan on the individual being stigmatized (Jenerette et
al 2011).
Stigmatization is the main reason college athletes and American Society of
Hematology are opposed to the mandatory sickle cell trait screening required by The
National Collegiate Athletes as prerequisite to athletic participation. American
Society of Hematology because of this ethical concerns recommends that universal
precautions that would protect all student athletes should be in place instead of
revealing the sickle cell trait status of student athletes (Ferrari et al 2015).

Sickle Cell Disorder Screening
Progress has been made in newborn screening since it was made mandatory in the
United States. Every State in the United States, the District of Columbia and U.S
territories mandates sickle cell disease for all newborn babies (Maakaron 2020).
When it became apparent that sick cell disease can no longer be ignored as a
significant public health problem, the United States congress in 1972 passed the
National Sickle Cell Anemia Control Act which authorized education, screening,
counseling, research and treatment programs for sickle cell disease (U.S Congress
1972). United States and other high income countries have instituted mandatory
newborn screening for SCD and for all at risk individuals which has contributed to
mitigation of mortality and morbidity associated with these disorders. In sickle cell
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endemic countries like Nigeria which leads the world in sickle cell disease
prevalence, such national newborn screening is still lacking. Because of this about 7090% of babies born with sickle cell die before age 5, only a small number of affected
infants and children make it to adolescence (Grosse et al 2011), and most of these
deaths occur before cases are diagnosed (Oron et al 2020). This is in contrast to high
income countries where more than 90% of individuals with SCD reach adulthood.
Uyoga et al (2019) reported that this dismal statistic of high mortality and morbidity
in sub Saharan Africa can be prevented or reduced by early diagnosis and supportive
care. Fraiwan et al (2019) reported that about 70% of deaths can prevented with early
diagnostic and treatment plans. In order to improve the health outcome of patients
with SCD and SCT successful screening, education, follow-up and management
programs must be implemented (de Montalembert et al 2019). Oron et al (2020) also
suggested that a major barrier to sickle cell prevention is lack of large-scale newborn
screening. Nnodu et al (2020) are of the opinion that newborn screening should be
integrated into existing primary health care. For meaningful preventive care to occur
there must be in existence a structured plan for early diagnosis and patient tracking
(Fraiwan et al (2019).
Very often in the United States, the story ends with screening of newborns.
Little or no effort is made towards communicating the findings to providers when
these babies transition to adults. As a result many who carry sickle cell trait are
unaware of their status. This has led to a steady increase in the incidence of sickle cell
disease since these people at risk are not being offered any education or genetic
counseling to make informed reproductive choices. Sox (2013) reported that the
biggest challenges facing NBS are timely follow-up and implementation of
comprehensive care. Also Kavanagh et al (2008) noted that wide variation in
reporting of screening results has led to delays in early intervention. El-Haj et al
(2018) noted that there is no mechanism of linking NBS systems with clinical data
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system. In order to facilitate transfer and exchange of information between NBS
program and clinical providers, medical record must be linked with NBS program
(Wang et al 2011). There are immigrants with unknown sickle cell status living in the
United States. Because there is no mandatory NBS from their home countries, these
immigrants and their offerings are also not screened in the United States until they
become sick. Routine screening of migrants from sickle cell endemic areas will help
reduce morbidity and mortality associated with SCD and ultimately save lives and
health care costs (American Society of Hematology 2019). They also recommended
that ED physicians should be educated to identify and quickly treat individuals with
acute sickle cell disease related events.
Call to Action
Even though so much has been done in term of diagnosis and pharmaceutical
therapies to reduce the burden of sickle cell disease on patient and family a lot still
has to been done in terms of palliative and curative care to enhance quality of life
(Siddiqi et al 2013). People with sickle cell disease have less access to comprehensive
team care than people with other genetic disorders like hemophilia and cystic fibrosis.
There is a great shortage of health care providers interested in and experienced in
caring for individuals with sickle cell disease, there are very few who wants to accept
Medicaid, coupled with lack of a standardized treatment guidelines (Stone 2015). The
combination of being both black and poor for the majority of children with SCD in
the United Sates presents a distinct set of challenge (DeBaun 2012). More education
and training is needed for effective emergency medicine, emergency nursing and
hospital care. Genetic education and counselling should be enhanced through mass
public education campaign. Just like other chronic disease like HIV/AIDS, diabetes
and hypertension, sickle cell should also be advertised on television, radio, social
media and other public communication outlets. If the public know that two carriers
cannot marry and that a carrier cannot marry a Sickler because of the chances of
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having a child with sickle cell disease, both the incidence and prevalence of the
disease will be greatly reduced. Blood and bone marrow transplant which is the only
cure for this disease should be made affordable. As at now only a very small number
of people with sickle cell disease are able to be transplanted.
Research and clinical trials have received very little attention as far as sickle
cell disease is concerned. Research is needed in the areas of stem cell, gene therapy
and editing and alternative donor transplants. Research on patient experiences has
revealed several themes that resonate among individuals with sickle cell disease and
caregivers. These include: mistrust and not being treated with respect, poor pain
management, being stigmatized as drug seekers and drug addicts and not being
included in decision making regarding their health.

Epidemiology of Sickle Cell Trait
Sickle cell Trait is a benign state of sickle cell disease occurring in over 300
million people worldwide. It is recognized globally to be of great public health
importance because of its reproductive and clinical significance (Pecker et al 2018).
According to CDC (2020) sickle cell disease and SCT affect particularly individuals
whose ancestors came from Sub-Saharan Africa, South and Central America, the
Caribbean, Saudi Arabia, India and Mediterranean countries such as Turkey, Greece
and Italy. In at least 40 countries sickle cell disease prevalence varies between 2 and
30% (Adam et al 2019). In Nigeria for example an estimated 150,000 babies are born
annually with sickle cell disease (Fraiwan et al 2019). In the United States,
approximately 100,000 individuals have sickle cell disease. In Americans 3 million
individuals have sickle cell trait affecting 8-10% of African American population
(CDC 2020). Sickle cell disease occurs among 1 out of every 365 black of African
American births. Sickle cell disease occurs among about 1 out of every 16,300
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Hispanic-American births. About 1 in 13 African American babies is born with sickle
cell trait
In 2010 it was estimated that over 60, 000 infants were born in the United
States with SCT according to the national Newborn Screening 10-year Incidence
Report. The incidence of SCT in participating States was 15.5 per 1000 newborn
overall, 73.1 among black newborns and 6.9 among Hispanic newborns (Ojodu et al
2014). Since only 44 States participated in this study, the incidence rate could have
been higher if all the 50 States participated. In this same study Florida had an
incidence of 25.9 cases per 1, 000 infants screened. A study by Reeves et al (2019) in
Michigan showed that blacks were disproportionately affected by SCD and SCT. In a
period of 1997-2014 they reported 592 SCA births and 33404 SCT in black children
representing 86.3% of SCA and 80% SCT cases respectively.

Why Providers must know the Sickle Cell Trait of their Clients.
Sickle cell trait although considered benign has significant health and social
implications. In malaria endemic areas, SCT protects carriers against malaria caused
by Plasmodium falciparum (Lansche et al 2018). This notwithstanding, SCT is a risk
factor for some adverse health outcome such as exertional rhabdomyolysis, sudden
death, chronic kidney disease, venous thromboembolism, preeclampsia and sickle cell
disease (Naik et al 2018). These health problems emphasize the importance of
comprehensive clinical and genetic evaluation to identify causes of health
complications reported in individuals with sickle cell trait (Sambuughin et al 2018).
Because of these health complications associated with SCT, evidence supports that
SCT may not be a benign condition after all (Nath et al 2020). Increasing knowledge
about these clinical outcomes can help inform genetic counseling, early treatment and
recommendations (Pecker et al 2018). Primary care providers can play a vital role in
early diagnosis and management of SCD and SCT. In order to make a significant
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impact on disease burden and economic burden of these orders more attention is
needed at primary care level (Galadanci et al 2014). Sickle cell disorders have
continued to proliferate in sub-Sahara regions like Nigeria because there is no
organized primary health care delivery system. According to Galadanci et al (2014)
management of sickle cell disorder in Nigeria is still suboptimal and they call for a
concerted effort to improve primary health care delivery system in the country. Here
in the United States primary care providers must double their effort to improve the
health outcome of patients with sickle cell disorders through awareness of the
existence of these disorders in their patients.

SCT and Exertional Rhabdomyolysis/Sudden Death
Sickle cell trait though benign is a risk factor for exertional rhabdomyolysis
particularly with dehydration and hot weather (Nelson et al 2016). Nelson et al
(2016) in a 4 year study of 48000 active duty black U.S soldiers reported incident rate
of exertional rhabdomyolysis of 12% and o.8% for soldiers with SCT and those
without SCT respectively. Sickle cell disease significantly elevates the risk for
exertional rhabdomyolysis and sudden death especially among athletes and military
trainees (Nelson et al 2016). Providers should be aware of this risk due to high profile
deaths involving rhabdomyolysis in athletes and military personnel. Nelson et al
(2018) concluded in their study that SCT was significantly associated with higher risk
of exertional rhabdomyolysis, but was not associated with higher risk of death.
Harmon et al (2012) reported exertion related deaths among black football players
participating in NCAA. Also Kark et al (1987) reported that SCT by a factor of 20-30
was a significant risk factor in sudden and unexplained deaths among black military
recruits. Because of this significant risks, many organizations like the NCAA and
military require a mandatory SCT screening prior to exposure to demanding physical
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training. This adoption of a universal screening protocol by NCAA and the military
has raised some concerns by organizations like American Society of hematology
association as they argue that it may lead to stigmatization and discrimination
(Thompson 2013).

Risk for Chronic Kidney Disease
Although sickle cell trait is often seen as being benign, carriers are at risk for
renal manifestations and complications such as impaired urinary concentration,
asymptomatic hematuria and papillary necrosis (Key et al 2010). Naik et al (2017)
suggested that hemoglobin variants including SCT have a role in kidney disease in
blacks. Naik et al (2014) also suggested that sickle cell trait may be an important and
unrecognized risk factor for renal disease in black population. Sickle cell trait and
sickle cell disease have been associated with faster kidney function decline in African
American patients (Nath et al 2020, Olaniran et al 2019). As reported by Munter et al
(2012), African Americans have a disproportionately higher risk of chronic kidney
disease progression to end stage renal disease when compared to whites and Asian
Americans. In a study by Naik et al (2014) of 15,97s of people that identified
themselves as African American, 1,245 were identified as carriers of SCT. The study
also showed that the incidence of CKD was significantly higher (20.7%) in carriers of
SCT than in noncarriers. In this study Naik et al (2014) concluded that among African
Americans in these cohorts, the presence of SCT was associated with an increased
risk of CKD, decline in eGFR, and albuminuria, compared with noncarriers. These
findings suggest that SCT may be associated with the higher risk of kidney disease in
African Americans.
SCT and Pregnancy Complications
SCT has been linked with various adverse outcomes in pregnancy, ranging
from maternal complications such as elevated risk of bacteriuria to potentially life-
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threatening entities such as pre-eclampsia and prematurity (Wilson et al 2020).
O’Hara et al (2020) postulated that for a pregnant woman being SCT positive is a risk
factor for pregnancy related hypertensive disorders showing that SCT has adverse
effect on reproductive health. In their retrospective study of 25,020 enlisted active
service women which comprised of 84% black women, they reported 30.4% of
overall pregnancy related hypertensive disorders attributable risk due to SCT status
and that those with SCT had higher health care utilization rates for all pregnancy
related hypertensive disorders including preeclampsia and eclampsia. These women
should be identified early in pregnancy in order to prevent these complications
(Hamdi et al 2006).
Hamdi et al (2006) studied pregnancy outcome in women with SCT. They
reported that incidence of anemia, abortion and neonatal death was significantly high
among women with SCT and therefore concluded that these women need increased
and special care during pregnancy, labor, puerperium and surgery. Taylor et al (2006)
also evaluated the obstetric outcomes and pathologic findings in pregnant women
with SCT. They reported a shorter average pregnancy duration and low birth weight,
acute ascending amniotic infection and meconium histiocytosis in subjects with SCT.
They also identified a significantly higher fetal death among women with SCT when
compared to the control group (3.5% vs 9.7%).
Sickle Cell Trait, Genetic Counseling and Sickle Cell Disease Prevention
Sickle cell disease is a disorder which can be prevented or even eradicated
through adherence to genetic counseling among subjects with SCT who are
considering having children. There is no cure at present for sickle cell disease the only
way to reduce the risk of transmission and prevent the health burden associated with
sickle cell disease is to make informed reproductive choices (Asgharian et al 2010).
Galadanci et al (2014) proposed the following as ways of reducing the devastating
effects of sickle cell disorders in Nigeria, training of healthcare workers, awareness
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and education, early diagnosis, health surveillance and referrals to specialists. MayoGamble et al (2019) reported that there is consistently insufficient knowledge about
the genetic inheritance pattern of SCD among people with sickle cell trait (SCT).
Premarital counseling is very advantageous in reducing both the incidence and
prevalence of SCT and SCD by targeting intending couples of high risk marriage and
offering them genetic counseling prior to conception (Alswaidi et al 2009). It is very
beneficial to invest in strategies that will reduce the mortality, morbidity, prevalence
and incidence of sickle cell disease. Some countries where sickle cell disease is
endemic have developed a very efficient genetic counseling and testing for
hemoglobinopathies. Success has been made in this regards in some Mediterranean
countries like Greece, Cyprus and Italy (Cao et al 2002). In some countries like
Nigeria and Cyprus religious organizations play very important role in this respect
offering premarital genetic counseling to at risk couples with very remarkable results
(Cowan 2009, Ezugwu et al 2019). In Nigeria members of Roman Catholic faith are
required to attend a pre-marriage course prior to wedding and this includes SCT
screening and genetic counseling (Ezechukwu & Chukwuka 2004). Even though
premarital counseling by religious bodies has raised some ethical issues namely
intrusion into marriage as opined by Ezugwu et al (2019), providers should not be
deterred from offering genetic counseling to SCT carriers who are thinking of having
children because of ethical concerns. This is because the health, social and economic
burden of sickle cell disease is enormous and far outweighs the ethical issues raised.
Ezechukwu and Chukwuka (2004) are of the opinion that this practice should be
encouraged and strengthened because of success it has achieved. Nnaji et al (2013) in
their study of sickle cell disease in Southeastern Nigeria reported that 2/3 of their
respondents will call off their marriage if there was risk of their offspring inheriting
sickle cell anemia.
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Individuals with SCT even though they are just carriers of SCD are at risk of
having children with sickle cell disease when they make babies with another SCT
carrier. Pre-conception counseling is therefore of essence in order to help individuals
make an informed reproductive decisions and choices and this will also have
remarkable impact on the epidemiology of the disease (Aneke & Okocha 2016).
Premarital counseling has been shown to have a great advantage in reducing the
prevalence of this disorder over newborn screening because premarital genetic
counseling is aimed at primary prevention while newborn screening addresses
secondary or tertiary prevention (Tamhanker et al 2008). It would be beneficial to
identify SCD carriers and at risk couples and educated them on patterns of inheritance
of SCD and health risks associated with SCD. According to Rance et al (2018),
education regarding sickle cell disease knowledge and genetic implications may help
women to make informed decisions regarding pregnancy. Increasing SCT awareness
through testing and proper education especially in practice settings will help mitigate
against the sequelae of SCT and perhaps decrease the incidence of sickle cell disease.
The application of SCT guidelines in practice can help educate patients and their
families which will help improve clinical outcomes for black patients through
implementation of modifiable factors. Proper implementation of SCT practice
guidelines will reduce the economic and social burden of SCT and sickle cell disease
both for the patient and the society. Aneke and Okocha (2016) suggested that it is
imperative to invest in w

Management Considerations for Individuals with Sickle Cell Trait
Most providers do not know the sickle cell status of their African American
patients. Even some patients and their families do not know their status due to poor
reporting system (Taylor et al 2014). This should be established during initial
encounter between the provider and the patients. Benenson et al (2018), postulated
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that for provider to provide an evidence based care to their patients with SCT, they
must be very conversant with the screening, health complications and routine
management of these patients. Sickle cell screening should be initiated immediately
in those individuals whose status is not known. Despite widely performed newborn
screening, there are individuals who were born before the mandatory newborn
screening and also there may be immigrants who were not screened in the countries of
their birth and many may be unsure of their screening results due to lack of
standardized reporting system (Vichinsky 2020). Also there is no standard way of
reporting SCT results when clients transition from babies to adulthood from one
provider to another. Information about SCT status of client seeking clearance for
sporting activities, competitive athletes and participation in other strenuous training is
very important. This information will help the provider in providing adequate
teaching to the client, review and reinforce healthy practices such as adequate
hydration to prevent adverse health events like rhabdomyolysis, exertional fatigue and
sudden death associated with SCT (Vichinsky 2020). Also the use of any supplement
that can exacerbate hypernatremia and dehydration should be discourage and should
not be prescribed to individuals engaged in strenuous physical activities (Vinchinsky
2020)
Providers should conduct appropriate laboratory testing for their patients
whose SCT status is known to detect early signs of kidney disease and renal cancer
which has been associated with SCT in African Americans. Laboratory tests which
will detect persistent albuminuria/proteinuria and serum creatinine should be ordered
and evaluated. Increased incidence of albuminuria often occur in individuals with
SCT (Sood et al 2019). Patients should be taught to seek prompt medical help for
hematuria and SCT carriers with unexplained and persistent hematuria should be
further investigated for renal complications using imaging (Benenson et al (2018).
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This will help the provider make appropriate referrals for further investigation of the
condition.
Pregnant individuals with SCT should be closely monitored throughout the
duration of the pregnancy and beyond. Sickle cell trait is associated with pregnancy
related hypertensive disorders such as preeclampsia and eclampsia and have increase
health care utilization (O’Hara et al 2020. Wellenstein et al (2019) found an
association between SCT and adverse pregnancy outcomes such as hypertension,
small for gestational age, diabetes and preterm delivery. Providers should refer their
clients with sickle cell trait who seek to have children to genetic counseling in order
to make appropriate reproductive choices. Vinchinsky (2020) advised that
communication of a positive SCT screening result must be accompanied by
appropriate counseling.
Individuals with SCT should also be educated that they cannot donate blood
for general blood supply (Vinchinsky 2020). Individuals who are SCT carriers at risk
for venous thromboembolism and therefore should be taught signs and symptoms to
recognize and report to their providers immediately. During air travel they should be
advised to move frequently and anticoagulation should be considered during surgery
and illnesses which can predispose an individual to thromboembolic events
(Benenson et al 2018).
Knowledge Gap;
Sickle cell disease and sickle cell trait have continued to be unsurmountable
problems due to lack of awareness and knowledge about these two disorders. Some
individuals with SCT do not know their status and even their healthcare providers are
also not aware of the SCT status of their patients. Efforts are not being made to
educate black communities on health implications of SCT through television
advertisements as seen with other health conditions such HIV/AIDS, obesity and
asthma. There is no public health awareness education on SCT and SCD and as such
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both prevalence and incidence of these diseases have continued to increase in black
communities. Knowledge gap also exist during transition from pediatric to adult care
due to lack of a standardized protocol of communicating sickle cell status from one
provider to another. This lack of communication also exists between patients and
providers because provider often do not collect information on SCT status from their
patients during initial encounter. There is no routine check-ups for individuals with
SCT which will help detect serious health conditions like chronic kidney disease early
and sudden death which occur sometimes in black athletes. Studies have shown that
SCT is no longer considered a benign condition.

Proposal of Solution
In order to prevent the health sequelae associated with SCT and prevent the
occurrence of sick cell disease, the following actions must be taken:
Standardized reporting method: Result of newborn screening should be reported
using a scandalized method and such results should be passed on to the next provider
when the patient transitions to adolescent/adult care.
Genetic counseling: This will lead to reduction in both the incidence and prevalence
of SCD assuming carriers make informed reproductive choices. According to
Ashorobi et al (2021) it is very essential that carriers of sickle cell trait are given
access genetic counseling making it possible for them to be we informed regarding
the fact that their offspring has the potential to inherit sickle cell disease. Genetic
counseling should be made available to individuals with SCT who are in childbearing
age. They will be educated on their status and implication for reproductive choices. It
is assumed that this will help them make informed choice. According to Ashorobi et
al (2021), genetic counseling has been shown to reduce the percentage of SCT and
SCD.
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Inclusion in medical record: Sickle cell trait status should be included in initial
patient assessment and form part of patient permanent medical record. Sick cell trait
status should be initiate during the first encounter between an African American
patient and his/her health care provider. The result of the screening should me made
part of the patients permanent medical record and should be made available to other
providers who may seek the patient’s medical record. This process will facilitate
sharing knowledge of a patient’s SCT status among health care providers.
Public Education: Mass public health education should be regularly done through
radio and TV ads. Television ads can be used to educate the population about SCT, its
health implications and precautionary measures. Enhancing and expanding the
knowledge of basic aspect of SCT and SCD are very important in disease
management and prevention. Knowledge of SCT will be very significant in helping
people make better choices which will improve their overall health outcome. Creamy
et al (2017) reported that only 38.1% of their study population have baseline
knowledge of sickle cell trait prior to being educated about SCT. After receiving
proper education 90.3% achieved better education. It is therefore imperative that
people with SCT and SCD should be educated about the inheritance of SCD, partner
testing, genetic counseling and prenatal diagnosis.
Routine follow-ups: All people with sickle cell trait should have routine follow-up
tests and labs to detect serious conditions early and apply proper management
protocols. This can be included in the annual physical examination. Primary care
providers should initiate and monitor laboratory results in all persons with SCT. This
will enhance preventative care and prompt referral to specialists.
Purpose/PICO Clinical Questions/Objectives
Purpose: The purpose of this project was to alert providers of the gap in knowledge
and practice concerning SCT in African American Patients and potential health risks
that African Americans are exposed to when their sickle cell trait (SCT) is unknown.
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The project also assessed the providers’ knowledge, attitudes and practices
concerning sickle cell trait.
PICO clinical question: Will educational Intervention to providers lead to change in
practice and best health outcome for African Americans with sickle cell trait?
•

P: How will providers and African Americans utilize SCT knowledge?

•

I: What can providers do to improve health using knowledge of SCT?

•

C: How will change in practice by providers improve health outcome?

•

O: going forth will African Americans with SCT have better health outcome?

Research Objectives
The project in addition to calling the attention of providers to this gap in practice also
investigated:
•

If the provider knows the SCT status of their African American patients, if yes
does patient know?

•

If SCT status is part of patient history taking during initial encounter

•

If providers are routinely screening their African American patients for SCT

•

If providers are utilizing the evidence base data that SCT poses serious health
risks for African Americans to guide management and treatment of illnesses

•

If those with SCT are routinely evaluated for SCT complications.

•

For providers who do not routinely screen their patients, they were asked if
they will incorporate SCT screening of African American patients to their
practice

•

The study also persuaded providers to screen patients of unknown SCT status
and to offer appropriate genetic education to SCT patients and monitor them
routinely for signs of serious complications.

Search Strategy
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An extensive and comprehensive review of peer reviewed articles that highlighted
sickle cell trait, its complications and management strategies was done. The
following databases were utilized: the Cochrane library database, Cumulative
Index to Nursing and Allied Health Literature (CINHAL), Medline, National
Institute of Health, Center for Disease Control and Prevention and World Health
Organization. Key search terms include sickle cell trait, SCT complications,
Providers’ knowledge, attitude and practice of SCT, Sickle cell trait management
strategies, genetic counselling and SCT prevention. Only articles published in
English Language were accessed.

Definition of Terms
Sickle cell Trait: Inheritance of one gene for normal hemoglobin and one for
sickle cell hemoglobin. It is a genetic carrier state
Health care Provider: an individual who is licensed or otherwise authorized by
State to provide health care services.
Genetic counseling: Getting information about how genetic disorders such as
sickle cell disease might affect you individually and your family.
Rhabdomyolysis: A breakdown of muscle tissue that releases a damaging protein
(myoglobin) into the blood which can damage the kidneys.
Sickle Cell Screening: Testing a person’s blood for abnormal types of
hemoglobin.
SCT Status: Knowing if one is a carrier of sickle trait.

Practice Question
The main objective of this study was to raise awareness about sickle cell trait and
health problems associated with it among healthcare providers. The practice
question therefore is “would an educational intervention for providers lead to an
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increase in knowledge of sickle cell, change in attitude and practice among
providers”? In order to answer this question a pretest-intervention-posttest
research design was used to study the knowledge, attitude and practice of
providers regarding SCT.
Conceptual Underpinning and Theoretical Framework of the Project
An implementation framework, Knowledge to Action framework (KTA) will be
used to examine the role that providers play in creating awareness of SCT and its
health implications. The KTA framework is used to guide knowledge translation into
practice (Crockett 2017). The KTA framework which consists of two iterative
process, knowledge creation and action cycle was developed in Canada in the 2000s
by Graham and his colleagues to solve the problem of confusing multiplicity of terms
used to describe the process of transforming knowledge into action (Graham et al
2006). According to WHO (2021), solution to some clinical problems may be found
in already existing knowledge. It is important to synthesize existing research data and
to contextualize the resulting knowledge prior to implementation (WHO 2021). The
knowledge of sickle cell trait already exist. The problem is that this knowledge is not
translated into action to prevent health complications associated with SCT. This
project seeks to identify this gap in knowledge and practice and offer solutions to
close this gap, hence ensuring best health outcome for African American patients with
SCT. Sickle cell trait disproportionately affect African Americans, however
awareness by providers and patients is often lacking. Based on KTA framework this
study will involve:
1. Problem identification (investigate of providers are aware of the SCT status of
their black patients.
2. Creation of awareness, coaching and persuasion
3. Outcome evaluation.
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Because KTA framework is iterative and dynamic it is often used in research in
healthcare and academic settings to solve problem targeted at patients, the public,
nursing and applied health professionals (Field 2014). As the process of KTA is
iterative, not only can it inform, components of the action cycle also feedback to
inform knowledge creation (WHO 2021). Xu et al (2020) in their study of
intervention to improve the quality of care transition for joint arthroplasty patients
concluded that KTA framework provides a logical and valuable tool for clinical
work. Their results also showed that using the KTA framework for joint
arthroplasty patients helped improve care transition.

Methodology
Introduction
This QI project will be used to effect changes in the way providers treat and manage
patients with SCT. Measures to monitor were selected, interventions to implement
were chosen and possible strategies to effect these changes were identified. Effort is
in the pipeline to adapt these changes to JHS, identify and deal with barriers that may
affect the adaptation of these changes. At the end of the project Plan, Do, Study, Act
(PDSA) will be used to push this initiative until all the providers have been educated.
The purpose of this project was to explore providers’ knowledge, attitude and
practices regarding sickle cell trait and to raise awareness that SCT is not a benign
condition. Also the project sought to find out if an educational intervention will lead
to change in practice among healthcare providers. This is because SCT has sequelae
of health complications. Evidence from literature showed that little to nothing is being
done as far as SCT and its management are concerned. Increased awareness of SCT
among providers and their patients is very paramount. The current gap in knowledge
and practice must be bridge by using evidence based practices in the management of
individuals with SCT.
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Study Design
The study made use of a quantitative pretest-intervention-posttest one group design to
explore and gain an in-depth information on what providers know and how they
manage individuals with sickle cell trait.
Approach and Rationale.
The study was done using a quantitative quasi-experimental design of one
group pretest-posttest design. The study participants came from internal medicine
team of Jackson Health system. There was no randomization of study participants and
there was no control group. The study participants were subjected to the same
treatment and assessment. This design allowed for the assessment of educational
intervention that was applied to the study population. The study is exploratory which
will help provide a detailed information about providers and sickle cell trait. A
pretest- intervention-posttest design was considered the best research design to study
providers’ knowledge, attitude and practice regarding sickle cell trait and its
complications. Pretest-posttest design as a form of quasi-experimental design allowed
for uncomplicated assessment of an intervention applied to the study participants. The
design made it possible to determine if educational intervention will lead to a change
in practice.

Setting and Location
The study was carried out at Jackson Memorial Hospital. Jackson Health System is a
non-profit tertiary care teaching hospital and the major teaching hospital of the
University Of Miami School Of Medicine. Its organizational structure helped me
achieve the goals of this project. Jackson Health System being a county hospital
provides high quality care to everyone irrespective of insurance status. Most minority
patients who do not have health insurance are issued a Jackson Card which enables
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them to access health care. Jackson takes care of the vast majority of black patients
with sickle cell disease and their families and has a dedicated center for sickle cell
patients. Dr. Thomas Harrington, a specialist in sickle cell disorders follows most
sickle cell patients who come to Jackson Memorial Hospital for their health care
needs. This makes Jackson Memorial Hospital an ideal place to carry out this project.
Jackson health system has hospitalist team. Hospitalists provide general medical care
to hospitalized patients. They lead the hospital medical team, coordinating care for
inpatients. Hospitalists see patients for the duration of a hospital stay. If the patient
has a chronic condition that requires multiple stays, the hospitalist may see them more
frequently. The study population for this project were the Hospitalist at Jackson
Memorial Hospital.

Study Population
The target population for this study was the hospitalist providers of Jackson
Memorial Hospital, medical doctors, nurse practitioners and physician assistants, of
all genders. Thirty participants participated in the study. The inclusion criteria are
being a member of hospitalist at JMH and English speaking. Exclusion criteria was
non-speakers of English language. English language was the only language that was
used for this project.
Recruitment and Consenting.
Recruitment was done electronically through the medical director of the
Hospitalist. Email letter was used to recruit participants comprising of 30 providers
medical doctors, nurse practitioners and physician assistants. The recruitment letter
(Appendix C) explained the purpose, benefits and conditions for participation.
Consent for participation was obtained by asking the participants to click yes to be
taken to the study questionnaire. The recruitment letter also explained to the
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participants that they will not be compensated for participating in the study and also
that they would not incur any cost.
Sampling
Data was collected using non-probability or convenience sampling method in
order to make the process less cumbersome. Basic data and trends regarding sickle
cell trait and its management were collected without the complications of using a
randomized sample.
Convenience sampling was done using a structured questionnaire for data
collection. Convenience sampling is very easy to carry out and may generate useful
data and information that would have been impossible with probability sampling
techniques which require more formal access to lists of populations (Etikan2016,
Laerd dissertation 2020). Participants were recruited until saturation was reached
Sample Size.
Thirty providers were recruited for this study. A good maximum sample size is
usually 10% as long as it does not exceed 1000 (Davis 2021). There are about 200
members of internal medicine teams throughout Jackson Health System and 10% of
that is 20. Sample size of 30 exceeds the 10%. A t-test can be done with much less
than 30 participants.
Duration of Data Collection
Approval for this project was obtained from Florida International University
IRB and Jackson Health System Nursing Research and Evidence Based Practice
Council as well as Council of Chief Nursing Officers of Jackson Health System
(Appendices A, B) The project ran for three months. Participants were allowed to exit
the study at any time since participation was entirely voluntary.

Data Collection
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A pretest-posttest design was used for data collection .A pretest-posttest questionnaire
was created and uploaded to a software Qualtrics (Appendix D). After participants
gave their consent they were taken to the study site to complete a pretest questionnaire
in order to collect baseline data. After three weeks a PowerPoint presentation
containing Evidence based facts about sickle cell trait and its management was sent to
participants. After two weeks the participants were prompted to return to the study
site to complete the post-test portion of the pretest-posttest survey. Change from
intervention applied was measured by comparing pre-intervention data to postintervention data. In order to draw valid conclusion same respondents took part in
both the pretest and posttest surveys.

Intervention/Instrumentation
Two instruments were used for this study namely a structured questionnaire
and a power point of educational intervention. The pretest and posttest questionnaire
has 31 questions (appendix D) divided into three sections, knowledge, attitude and
practice. The questions were developed from findings from the extensive literature
review done. The use of pretest-posttest method made it possible to determine if
educational intervention made any impact on knowledge, attitude and practices of the
providers.

Educational Intervention
An educational power point was developed which summarizes information about SCT
and its management (appendix E). The educational intervention was expected to last
10 minutes. Included in the power point are information about SCT, complications
associated with SCT, evidence based management practices and recommendations
that will ensure best health outcome for individuals with SCT.
Data Analysis

38
Data coding and analysis was be done using Qualtrics/SPSS coding software.
All data analysis were done using SPSS. Results of the pre-test and post-test surveys
were scored with percentage and a mean score calculated. The scores were organized
according to a topic domain and were compared for improvement. Descriptive
statistics was used to primarily describe the data collected explaining how many
respondents undertook the desired behavior, what range of answers were, description
of central tendency and the spread of the data. The results of the pretest and posttest
were analyzed for significant difference using paired t-test.

Project Evaluation
The study was designed with accepted principle with research method which was
clear and feasible. The research question, which was “would an educational
intervention lead to a change in practice and best health outcome for African
Americans with sickle cell trait” was very clear and well defined at the beginning of
the project. Both the instrument used for the study and the study design were designed
to answer the research question.
Sample size was representative of the study group. More than 10% of the study
population participated in the study. According to Davis (2021) a good maximum
sample size is usually around 10% of the population as long as this does not exceed
1000. More than 10% of the Internal medicine teams of JHS participated in the study.
Appropriate research design was applied to this study. The design allowed for the
same intervention and assessment to be applied to the same group. It was able to
measure change resulting from intervention by comparing the pretest data to the
posttest data.
Quasi experimental design lacks randomization and therefore it does not eliminate the
problem of confounding variables. Quasi experimental design makes it possible to
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know with some level of confidence whether a particular intervention caused a
change.
SPSS was used for data coding and analysis. This is an appropriate data analysis
software for this type of study to compare pretest information to the posttest
information.
Discussion and conclusion were consistent with the study results. Ethical standards
were met throughout this study. Informed consent was obtained. Participants were
accurately informed of the purpose, methods, risks and benefits of the study. They
were giving the opportunity to make a voluntary decision about whether to participate
in the study. Respect of human dignity, confidentiality and privacy were taken into
consideration. The participants were not exposed to any risk or harm Answers to the
research question will contribute to improving the health of African Americans with
sickle cell trait by improving management protocol. To make sure this study was
ethically acceptable before it started approval from FIU IRB and JHS Nursing
Research and Evidence Based Council was obtained.

Protection of Human Subjects
No risk to participants occurred during this study. Participants did not provide
any personal identifier, no personal information was collected. Explanations were
provided to participants electronically periodically and as needed. This was highly
adequate to collect information required for this study. It was not possible for me to
associate a participant to the study and it was not possible for anyone to be link back
to his/her answers. The questionnaire which was used for data collection was only
assigned numbers which did not represent any individual or information from the
participants. Consent was obtained electronically and data collected was stored
electronically in my personal desktop computer which is password protected. My
computer is not shared with any other individual.
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Benefit to Society
This study will create awareness of SCT and its health risks. Given the large
number of people with SCT it is important that healthcare providers be aware of these
associations. This will help providers to target activities and programs that will result
in improvement in health outcome for African Americans. This awareness will also
lead to reduction in the prevalence of sickle cell disease through appropriate genetic
counseling since SCT has important reproductive consequences with a risk of having
a child with sickle cell disease. Reduction in incidence of sickle cell disease will lead
reduction in morbidity and mortality associated with sickle cell disease and hence
reduction in healthcare costs.

Results/Interpretation of findings
The purpose of this project was to alert health care providers about the gap in
knowledge and practice concerning sickle cell trait, provide evidence based practice
measures to properly manage those with sickle cell trait and to study providers’
knowledge, attitude and practice concerning sickle cell trait.
A convenience sampling approach was used for data collection. The project was
conducted over a period of three months and a total of 30 health care providers were
recruited for this study. Data analysis was done using paired t-test that compared
changes in the mean scores between pretest and posttest data. All data analysis was
done using SPSS 24.0

Demographic Characteristics
Overall, twenty-one (70%) respondents completed both pre- and post-intervention
questionnaires and were included in the analysis. Thirteen of the respondents were
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males (61.9%) and 8 (38.1%) were females. Three (14.3) of the respondents identified
as Black or African American, 4 (19%) white, 12 (57.1%) Hispanic, while two
participants (9.5) identified as others. Eleven of the 21 (52.4%) respondents were
MDs, 8 (38.1%) NPs and 2 (9.5%) PAs. Most of the participants had 1-3 years of
experience (15/21, 71%), while three each (14%) had 4-7 years and greater than 10
years of experience. Details of participants’ characteristics are presented in Table 1.

Table 1.
Participants’ Characteristics
Characteristic
Gender
Male
Female
Ethnicity
Black or African American
White
Hispanic
Other
Experience (Years)
1-3
4-7
>10
Profession
MD
NP
PA

Frequency (%)
13(61.9)
8 (38.1)
3 (14.3)
4 (19)
12(57.1)
2 (9.5)
15 (71)
3 (14)
3 (14)
11 (52.4)
8 (38.1)
2 (9.5)

Total score pre vs post intervention
From the 30 healthcare providers recruited for this study only 21(70%) successfully
completed both the pretest and posttest. Table 1 shows the healthcare providers’
demographic characteristics. The pre-intervention KAP score of the respondents
showed some improvement in the posttest score after the educational intervention was
applied. To determine whether or not the intervention had an impact on participants’
overall score on the survey, participants’ total scores were compared using the paired
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t-test (table2). The mean score pre-intervention was 83.0(SD 15.5) and the mean score
post-intervention was 88.4(SD22.6). Although the mean total score was higher postintervention, this difference was not statistically significant (mean difference =5.4,
p=0.223

Table 2.
Total (Overall) Scores Pre- vs. Post-Intervention (Paired T-Test)
Pre-Intervention
Post-Intervention
Mean 83.0 (SD 15.5)
Mean 88.4 (SD 22.6)

P-value
0.223

Knowledge score pre vs post intervention.
Following the educational intervention knowledge scores significantly improved.
Participants’ knowledge of SCT scores were compared using the paired t-test (table
3). The mean score pre intervention was 23.6 (SD 5.4) and the mean score post
intervention was 29.3 (SD 7.1). There was a significant increase in knowledge scores
when comparing pre and post intervention (mean difference =5.7, p=0.045).
Table 3.
Knowledge Scores Pre- vs. Post-Intervention (Paired T-Test)
Pre-Intervention
Post-Intervention
Mean 23.6 (SD 5.4)
Mean 29.3 (SD 7.1)

Figure 1

P-value
0.045
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Attitude score pre vs post intervention
Most healthcare providers showed positive attitude towards SCT pre and post
intervention. Almost 100% of the respondents believed that SCT is of public health
importance and that the public should be educated on the health and reproductive
implications of SCT. To determine whether or not the intervention had an impact on
participants’ attitude towards SCT, participants’ attitude scores were compared using
the paired t-test (table 4). The mean attitude score pre-intervention was 37.3 (SD8.8)
and the mean attitude score post intervention was 36.3 (SD 10.8). However when the
mean attitude scores pre and post intervention were compared using paired t-test,
there was no significant difference (mean difference =1.0, p=0.545).

Figure 2
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Table 4.
Attitude Scores Pre- vs. Post-Intervention (Paired T-Test)
Pre-Intervention
Post-Intervention
Mean 37.3 (SD 8.8)
Mean 36.3 (SD 10.8)

P-value
0.545

Practice score pre vs post intervention
100% of the providers see black patients regularly in their practice but only 50% of
them know the SCT status of some of their patients. The results collected for practice
for pretest and posttest were almost similar and 90% also said that they will be more
proactive in managing their patients with SCT. Most of the respondents (85%) for
both pretest and posttest strongly agree that SCT should be included in the patients’
medical record. There was no significant difference in the practice of the providers
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Table 5.
Practice Scores Pre- vs. Post-Intervention (Paired T-Test)
Pre-Intervention
Post-Intervention
Mean 22.1 (SD 4.4)
Mean 22.9 (SD 5.6)

Figure 3

Discussion

P-value
0.604
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How results compare to review of literature
Even though the knowledge of SCT improved among healthcare providers after the
educational intervention, unfortunately in reality the actual management of people
with SCT is still deficient. This may be attributed to lack of established clinical
protocol to manage patients with SCT. This can also be attributed to the fact that some
providers pre-intervention considered SCT a benign condition. Nath et al (2020)
pointed out that SCT should no longer be considered a benign condition. SCT under
conditions of low oxygen such as high altitude may become a pathologic risk
Maakron (2020). Sickle cell trait has clinical sequelae such as exercise related injury,
heat stroke, sudden death, muscle breakdown (CDC 2016), renal complications (Naik
et al 2018), venous thromboembolism (Benenson et al 2018), pregnancy
complications (Tantawy 2014) and risk of having a child with sickle cell disease due
to lack of screening and genetic education (CDC 2020). These health problems
emphasize the importance of comprehensive clinical and genetic evaluation to
identify causes of health complications reported in individuals with SCT
(Sambuughin et al 2018). The gap between knowledge and practice was also evident
when 66.67% of the providers know that black athletes and military trainees are at
risk of sudden death from muscle breakdown due to SCT, yet only 58% of the
respondents strongly agree that black athletes and military trainees should be first
screened for SCT before issuing clearance for these individuals to participate in
strenuous activities and 58.33% do not screen their patients of unknown SCT status
and 58.33% also do not obtain family history of sickle cell disorders from their black
patients. Mainous et al (2015) reported that people with SCT are often not screened
because such individuals do not usually manifest any visible symptoms as seen in
people with sickle cell disease. This is why educating the providers is extremely
important to bridge this gap between knowledge of SCT and practice among
providers. Galadanci et al (2014) pointed out that in order to curb problems associated
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with SCT attention is needed at primary care level. Benenson et al (2018) suggested
that in order to provide evidence based care to at risk population providers must be
aware of the SCT status of their clients, potential health complications of SCT and
routine management of individuals with SCT. It is also important for providers to
know that they should implement SCT screening not only for newborns but for
everyone whose status is unknown (Ashorobi et al 2021). The importance of
screening is further buttressed by report of Memish et al (2011) who reported a
decrease in the number of individuals with SCT marrying another carrier due to
premarital screening and genetic education. Benenson et al (2018) also emphasized
that SCT screening should be carefully documented and communicated to affected
individuals and their providers.
Most people with SCT and their families do not know their SCT status neither
do their providers. In this study only 8.33% know the SCT status of all their black
patients, 41.67% do not have SCT status in their patients’ medical record and only
16.67% obtain this data during initial patient encounter. This has been attributed to
poor reporting system (Taylor et al 2014) and lack of standardized methods or
protocols for alerting families and healthcare providers about SCT status (Ojodu et al
2014). CDC (2020) emphasized that providers must know their clients’ SCT status
and people with SCT should be properly informed of their SCT status and they should
also be educated about possible health problems and reproductive considerations.
Vinchinsky (2020) advised that communication of a positive SCT screening result
must be accompanied by appropriate counseling.
This study reemphasized that educating the providers will change practice for better
and improve the way individuals with SCT are treated and managed. The study
demonstrated the significance of making evidence based facts about disease
management available to healthcare providers. Factors such as unawareness of health
risks, lack of knowledge SCT management considerations and negative attitude
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negate proper and adequate management of individuals with SCT. These problems
can be minimized or totally removed through provision of adequate training and
access to updated information on SCT. Gonzalez-Formoso et al (2020) in a
randomized study using educational intervention in family and community service to
improve safety culture reported that educational intervention given to Residents was
effective in improving patient safety culture. Also Farha et al (2018) reported that
following an educational intervention knowledge and perception score of providers
regarding pharmacovigilance significantly improved. In their study providers showed
an overall low knowledge score (7.8%) pre-intervention but showed a remarkable
increase (67.9%) post-intervention. This is in agreement with the findings of this
study, the mean score for knowledge improved after the educational intervention and
the difference in the mean scores for pretest and posttest were found to be statistically
different.
Knowledge of healthcare providers regarding SCT will have major impact on the
practice and management of SCT patients. If well-educated on the disease process and
management there will be a positive drive towards better management practices
regarding SCT, hence improving the health outcome of those with SCT. Also
providers’ attitude towards a disease plays an important role in affecting healthcare
providers practice and management of diseases. Inadequate Knowledge, awareness
and perception ultimately affect practice. Abu Harmour et al (2017).

What was learned from the QI project
Lessons learned from this project include:
▪

People with SCT do not receive adequate care since more than 50% of the
providers consider SCT a benign condition.
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▪

Even though 100% of the providers treat black clients, more than 50% of them
do not know the SCT status of their patients.

▪

Providers must be made aware that SCT is not a benign condition and they
must be educated on how to manage patients with SCT using Evidence Based
strategies in order to mitigate serious health problems in these patients.

Limitations of the project:
The study made use of a quasi-experimental design which lacked both randomization
and a control group. Validity of the study is difficult to achieve as the design has
inherent flaws such as lack of sample randomization. All aspects of this project were
done online. When the questionnaire was sent to the providers some did not receive it
because it went to their junk/spam mails instead of their inbox and I did not realize
this until it was too late. Thirty percent of the providers completed either only the
pretest or the posttest and as such their responses were not included in the final
analysis. These definitely must have affected the findings of this study.

Implications for Advance Practice Nurse:
Advance Practice nurses can champion how the findings of this QI project will
influence clinical practice and policy changes to mitigate health problems associated
with SCT. This will create a more transparent and sustainable healthcare service to
which nurses are the change makers. Making people with SCT aware of their status is
essential in reducing both the incidence and prevalence of SCD through genetic
counseling. Providers will make it part of practice to collect information about sickle
cell disorders during initial patient encounter, screen all their black patients for SCT if
status is unknown and refer those with SCT for genetic counseling especially those in
child bearing age. These measures will reduce incidence of sickle cell disease and
prevent the morbidity, mortality and cost associated with sickle cell disease.
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Equipping providers with knowledge of SCT will improve how SCT is managed.
Sickle cell trait will no longer be treated as a benign condition by providers. With
providers being proactive through patient and family education, early referral to
genetic counseling, routine laboratory testing and checking SCT status before issuing
clearance for participation to sporting activities providers will be mitigating health
problems associated with SCT in their African American clients. Knowing the
connection between SCT and sudden death in athletes and military trainees will help
prevent sudden death in these through anticipatory precautionary measures to prevent
dehydration and subsequent rhabdomyolysis. Early laboratory testing will also help
prevent chronic disease, venous thromboembolism, hematuria and other disease
sequelae associated with SCT.
According to Melander et al (2020) the healthcare system can benefit immensely from
a well-designed and meaningful project through improved service delivery, patient
outcomes and use of evidenced-base practice in routine care. They are also of the
opinion that DNP project will help reduce gaps in practice, promote scholarships and
foster the emergence of innovations. Paplham et al (2015) also reported that DNP
projects has the ability to ensure improvement in patient and system outcomes as well
as lead to optimization of health trajectories

How this project will change practice
This project will change practice if providers start collecting their patients’ SCT
status during initial encounter, making it part of medical record and communicates
such results to other providers during transfer/transition of care. This will ensure early
management and continuation of care for patients with sickle cell trait. This will help
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mitigate adverse health problems in African American patients and ensure best health
outcome for them.
Recommendations for future studies
Future research is needed to actually go into patients’ medical records to see if
providers are adhering to recommendations suggested in this QI project like collecting
SCT status during initial patient encounter and making it part of patient’s permanent
medical record.
Conclusions
Providers KAP is very essential for effective management of clients with SCT.
SCT awareness among providers and clients will help reduce morbidity and mortality
associated with sickle cell disorders.
SCT is not a benign condition
More attention should be paid to SCT because of its clinical squeal
Practice modalities can be modified to mitigate health problems. Gaps in practice
must be bridged for best health outcome for those with SCT.

Plan for Dissemination:
A research study will only be complete if the study findings are disseminated. Sharing
study findings with other nurses, interdisciplinary colleagues, policy makers and the
public is very paramount for the advancement of nursing science. Sharing a DNP
project findings gives one the opportunity to advance the art and science of nursing.
This can influence clinical practice, nursing education, health policies and research.
Dissemination Goals.
The goals for disseminating the findings of this DNP QI project include:
To increase the reach of evidence by making providers are that SCT is no longer
considered a benign condition and that it is associated with sequelae of serious health
problems.
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By exposing the evidence based management of SCT, the project will be increasing
the ability to use and apply evidence to practice.
Internal Dissemination
Results of this project will be made available to JHS leadership. Hopefully it will be
accepted, standardized and incorporated into policy and procedure of the hospital.
External Dissemination Channels
The three Ps of project dissemination will be used to disseminate the findings of this
project, posters, presentations and papers. An abstract will be submitted to the Sickle
Cell Association of America for presentation during their annual conference.
A poster presentation will be submitted to the Florida Nurses Association annual
conference and finally the results of this project will be published in a peer reviewed
journal. The results will also be made available to the medical director of JMH
Hospitalist for dissemination to members.
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Appendix D

Questionnaire/Survey Project
Questionnaire for Healthcare Providers
I am a DNP student from FIU conducting a study which is aimed at raising awareness
about Sickle cell trait (SCT) I am carrying out an evaluation of some of medical
providers to study their knowledge, attitude and practice with regards to SCT in order
to improve health outcome for those with SCT. Thank you for taking the time to fill in
this questionnaire; it should only take 10 minutes. Your answers will be treated with
complete confidentiality, you will be entirely anonymous. If you have any questions
about this questionnaire, I will be glad to answer that.
I am
MD 
NP 
PA 
I have been in practice for
1-3 years,
4-7years
8-10 years
Greater than 10 years






Section A Knowledge
1. How will you rate your knowledge of sickle cell disorders: (please tick one)








Poor
Fair
Good
Very good
Excellent
Not sure

2. Sickle cell disorders predominately affect which population (please tick one)
Hispanics
Blacks
Caucasians
Native Americans
Don’t know
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3. Is sickle cell trait is a benign condition?
Yes
No




4. People with sickle cell trait are at risk for (please tick all that apply).
Rhabdomyolysis
Sudden death
Thromboembolism
Kidney disease
stroke
Anemia








5. When two people with SCT make baby, their chance of having a child with SCD
is (please tick one)
100%
75%
50%
25%
Not sure
0%








6. Which of the following is sickle cell trait genotype? (please tick one)
Hb SC
Hb as
Hb ss
Hb SD
Hb aa







7. All black newborn babies are screened for sickle cell disorders?
Yes
No
Not sure
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8. Which of the following is true regarding SCT and blood donation (please tick 0ne)






SCT carriers can donate blood to general population
They can donate blood to people with SCD
They cannot donate blood to cancer patients
Don’t know

9. There is increased risk of thrombosis with hormonal birth control in those with
SCT.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree


10. Athletes and military trainees with SCT are at risk of (Pick all that apply0






sudden death
Exertional rhabdomyolysis
Dehydration
Hemorrhage

Section B Attitude
11. Do you believe that SCT is of Public Health importance?
Yes
No




12.The public should be educated on SCT through public mass media: (please tick
one)
Strongly agree
Agree
Neutral
Strongly disagree
Disagree







13. Every black patient should be screened for SCT and the result communicated to
them
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Strongly agree
Agree
Neutral
Strongly disagree
Disagree

14.







How important is it for a provider to know the SCT status of their black
patients?






Very important
Quite important
Not very important
Not at all important

15.

Knowledge of SCT status by both patient and provider will lead to a better
health outcome for the patient.
Strongly agree
Agree
Neutral
Strongly disagree
Disagree

16.







Patients with SCT should be made aware of the reproductive implication, risk
of having a child with SCD
Strongly agree
Agree
Neutral
Strongly disagree
Disagree







17. Referral for genetic counselling should be included in the management protocol
for patients with SCT
Strongly agree
Agree
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Neutral
Strongly disagree
Disagree





18. Knowing that SCT is no longer a benign condition, should clinicians be more
proactive in screening their black patients for SCT?




Yes
No

19. Routine monitoring of those with SCT is very important to avert serious health
problems
Strongly agree
Agree
Neutral
Strongly disagree
Disagree







20.Do you believe that there is stigma attached to sickle cell disorders and this may
prevent disclosure of SCT status by patients?
Strongly agree
Agree
Neutral
Strongly disagree
Disagree







Section C Practice
21. Do you see black patients on regular basis?
Yes
NO




22. How many of your black patients do you know their SCT status?
All of them
Some of them
None of them






23. Does any of your black patients have their SCT status in their medical record?
No
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Yes

24. Do you agree that SCT status should be included in patient’s permanent medical
record







Strong agree
Agree
Neutral
Strongly disagree
Agree

25. Is it part of your practice to obtain SCT status during initial encounter while
obtaining medical history?
No
Yes




26. Do you ask your patients for family history of sickle cell disorders?
Yes
No




27. Do you screen your black patients for SCT if their status is unknown?
Yes
No




28. SCT status should be communicated to other providers during transition/transfer
of care.
Strongly agree
Agree
Neutral
Strongly disagree
Agree







29. Black patients who seek clearance for sports or military training should be
screened for SCT
Strongly agree
Agree
Neutral
Strongly disagree
Agree







30. Will you routinely monitor your patients with SCT for other health complications
if this has not been your practice?
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Definitely
Maybe
It is already part of my practice
No

31. Do you agree that genetic counselling is important in the eradication of sickle cell
disease?
Strongly agree
Agree
Neutral
Strongly disagree
Agree







Thank you very much for taking the time to complete this questionnaire.
If you have any other comments, please add them below:
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DNP Table of Evidence
Author/Date

Theoretical Research Focus
framework

Methodology

Aneke &Okocha
2016

None

How will
genetic
counseling and
testing reduce
prevalence of
sickle cell
disease?

Review of
Databases

Asghrian et al
2010

None

Qualitative
study using
focus groups

Ashorobi et al
2021

None

How do people
with SCD & SCT
face challenges
of making
informed
reproductive
decision?
Is sickle cell
trait a benign
condition?

Benenson et al
2018

None

Adverse
conditions
associated with
SCT

Review of
evidence

Creary et al 2017

None

SCT knowledge
and health
literacy in
caregivers

Qualitative
focus group
training

Crockett 2017

KAT

Knowledge to
action in
research

Analysis of KAT
framework

Etikan et al 2016

None

Comparison of
convenience
sampling and
purposive
sampling.

Review of
articles

Literature
Review

Findings that help
answer EBP
question
Current utilization
of genetic
counseling in
Nigeria is
unacceptably low.

Conclusion

Need for
massive
education of
the population
to increase
understanding
of SCD and
need for
voluntary
testing.
Findings enhance
Educational
the need for
intervention
reproductive
necessary to
education.
aid in making
informed
reproductive
decision.
Adverse conditions SCT is not
associated with SCT completely
benign and
patients should
be managed
aggressively.
SCT associated with Through
renal
appropriate
complications,
screenings and
thromboembolism, interventions
rhabdomyolysis,
NPS can
and sudden death. mitigate health
problems
associated with
SCT.
Awareness of SCT
Knowledge of
improved with in
SCT improved
person education
with
intervention
educational
intervention.
KAT provides
KAT increases
practical and
validity and
systematic method rigor of
to research
research.
No method is
Choice of
better than the
technique
other.
depends on
nature and
type of
research.
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Ezechukwu et al
2004

None

Pre-marriage
counseling as a
tool for sickle
cell disease
awareness in
Nigeria.

Qualitative
research, using
questionnaire,

Pre-marital
screening and
genetic counseling
very common
among Roman
Catholics.

Such
premarital
screening
should be
encouraged
and expanded
to schools.
Further studies
needed to help
inform
strategies to
reduce stigma
in these
vulnerable
group.

Ezenwa et al
2016

None

Descriptive
comparative
study.

There is association
of stigma with
fatigue, anger,
anxiety and
depression in
patients with SCD.

Ferrari et al 2015

None

Is there an
association
between
stigma and
physical and
emotional
symptoms in
patients with
SCD,
SCT screening
of Collegiate
athletes, ethical
reasons for
reform.

Analysis of
NCAA and
ethical concerns Collegiate
community must
address the
shortcomings of
the current
screening program.

Universal
precaution
should be
implemented
for the benefit
of student
athletes.

Field et al 2014

KTA

Using
Knowledge to
action
framework in
practice.

Citation analysis KTA framework can
and systematic
be applied to
review.
healthcare and
academic settings
with projects
targeting patients
and general public.

Fraiwan & Hassan
2019

None

Advancing
Healthcare
outcome for
SCD
management in
Nigeria using
Mobile Health
Tools

Pilot population
study.

System capable of
generating
information for all
cases of SCD, track
hospital visits,
appointments, lab
tests

Galadanci et al
2014

None

Common and
available
management
practices for
SCD in Nigeria.

Questionnaire
survey

Existence of
variable and poor
utilization of
standards of care
practices for SCD
patients in Nigeria.

Gibson & Rees

None

Complications

Commentary/ex SCT is linked to

When KTA is
part of
knowledge
translation it
guides action in
ways that
ensure theory
fidelity.
Increased
access to
diagnosis and
treatment for
all people with
sickle cell
disorders is
very important
to their
survival.
The care of
people with
SCD is still
suboptimal in
Nigeria and
urgent need to
address the
problem
especially at
primary care
level.
Sickle cell trait
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2016

of sickle cell
trait

pert opinion

Hamdi et al 2002

None

Assessment of
pregnancy
outcomes in
women with
SCT.

Labor room
records, patient
files and
computerized
files.

Harmon et al
2012

None

SCT as a cause
of sudden
death in NCAA
athletes

Housten et al
2016

None

Janzen et al 2016

KTA

Kark et al 1987

None

Assessment of
the feasibility
of community
based SCT
education and
testing
intervention.
Will use of KTA
improve
outcome for
stroke
patients?
SCT as a risk
factor for
sudden death
in military
trainees

Review of
causes of all
cases of sudden
death in NCAA
student
athletes from
January 2004 to
December
2008.
Mixed-methods
cross sectional
study.

Kavanagh et al
2008

None

Communication
of positive
newborn
screening for
SCD and trait.

Analysis of
autopsy and
clinical records
of 2 million
trainees from
1977 to 1981.
Survey research

splenic infarction at
high altitudes,
venous
thromboembolism,
renal damage and
exercise collapse.
The incidence of
abortion and
neonatal deaths in
previous
pregnancies was
significantly
increased among
women with SCT.

The risk of
exertional death in
football players
with SCT was 37
times higher than
in players without
SCT

Community base
SCT testing can be
successfully
implemented and
may increase
knowledge of SCT
status.
KTA was able to
change clinical
practice and
promotes use of
EBP in stroke rehab
Military trainees
with SCT have a
significantly
increased risk of
sudden death
during physical
training.
Wide variation
exists in
stakeholder
notification of NBS
screening results
for SCD and trait by
birth location.

is not a benign
condition.

Pregnant
women with
SCT need
special care
and attention
during
pregnancy,
labor,
puerperium
and surgery.
Exertional
death in
athletes with
SCT occurs at a
higher rate
than previously
appreciated.

Screening will
increase the
number of
people who
know their
status.
KTA lead to
improved EBP
in stroke
rehabilitation.
There is
association
between SCT
and sudden
death with
physical
training.
This variation
may affect
effectiveness
of NBS
prohrams.

85
Key et al 2010

None

Sickle Cell Trait
complications.

Review of
evidence

SCT is a risk factor
for certain adverse
health outcomes.

Research to
better
characterize
the
consequence
of SCT is
needed to
providing
better
counseling on
any associated
health risks.

Maakaron 2020

None

Sickle cell
anemia workup

Newsletter and
perspective
from expert
opinion.

Morbidity,
frequency of crisis,
degree of anemia
and organ system
involvement vary
considerably from
individual to
individual.

Mainous et al
2015

None

Study of family
physician’s
attitude
towards SCD
management.

Only 20.4% of the
respondents felt
comfortable with
treatment of SCD.

Mayo-Gamble et
al 2019

None

Perspectives of
adults with SCT
on information
needed to
make informed
reproductive
decision.

Memish et al
2011

None

To assess
burden of SCD
and the
frequency of at
risk marriage
detection and
prevention.

Analysis of
survey
conducted by
the Academic
Family medicine
Educational
Research
Survey.
Descriptive
qualitative
study that
involved focus
groups
composed of
purposive
sampling.
Retrospective
Review,
premarital
couples
attending
premarital and
genetic clinics
with marriage
proposals
between 2004
and 2009.

Providers must
follow the
existing
evidence-based
guidelines on
screening,
diagnosis and
management
of complication
of SCD.
Family
physicians are
generally
uncomfortable
with managing
SCD patients

Highlighted unmet
information needs
for African
Americans with
SCT.

Inability of
effective
communication
within medical
and personal
settings about
SCT status.

The frequency of
voluntary
cancellation of
marriage proposals
among at risk
couples showed
more than 5 fold
increase between
2004 and 2009.

Premarital
screening
markedly
reduced the
number of at
risk marriages
which may
considerably
reduce the
genetic disease
burden.

86
Munter et al
2012

None

Racial
differences in
the incidence
of chronic
kidney disease.

Prospective
cohort study.

In this 20 year
study incidence of
CKD was higher in
African Americans
than whites.

African
Americans are
four times
more likely to
develop ESRD
than whites
due to various
risk factors
including SCT.

Naik & Derebail
2017

None

Sickle
hemoglobin
related
nephropathy.

Review of
evidence.

Renal dysfunction
is among the most
common
complication of
sickle cell disease.

Naik et al 2017

None

Risk of ESRD in
Blacks.

Cohort study

SCT is strongly
associated with risk
of progression to
ESRD in Blacks.

Early
knowledge will
provider
opportunity for
early
intervention.
Has great
implication for
genetic
counseling of
SCT carriers.

